Leadership and Governance
Andrew MacIsaac
CEO and Board Member
Over the past decade Andrew has successfully established over $75 million in partnerships between industry, academia, government, and donors, and developed catalysts for economic investment totalling more than $200 million. With a background in economics and public sector management, Andrew has worked with UBC, and the University of Alberta, and is currently the Assistant Dean for the Faculty of Pharmacy and Pharmaceutical Sciences. Andrew sits on the Edmonton Chamber of Commerce, Policy Committee, the Edmonton Health City Steering Committee, and the board of the Canadian Mental Health Association, Edmonton.
Greg Klak
Board Member
Greg Klak is the Vice President of Operations and General Manager for the Gilead Alberta manufacturing facility. Prior to the acquisition by Gilead in 2006, he spent 16 years with Raylo Chemicals providing custom manufacturing services to the pharmaceutical industry, including Gilead Sciences. Mr. Klak received both his B. Comm. and MBA degrees from the University of Alberta, and currently serves as a Board Member for BioAlberta.
Jason Pincock
Board Member
Jason is currently the Chief Executive Officer of DynaLIFE Medical Labs, one of Alberta’s largest private healthcare organizations. At over 1100 employees DynaLIFE is Canada’s most regarded multidisciplinary clinical laboratory organization and is recognized as one of Canada’s Best Managed Companies. Jason is a Certified Management Accountant, a graduate of the Queens Executive Program and a member of the Institute of Corporate Directors. Jason works with an ownership board, including OMERS and Laboratory Corporation of America (publicly traded) as well as a board of senior policy advisors.
Launa Aspeslet
Board Chair
Dr. Launa J. Aspeslet is CEO of TRIO, a global clinical research organization headquartered in Edmonton, running oncology trials around the globe. Before joining TRIO, Dr. Aspeslet was a biotechnology consultant working primarily with early stage companies to plan, implement, and follow through with the development strategy for their drug, device, or combination product. Prior to this, she was Chief Operating Officer for Isotechnika Pharma Inc., a former Edmonton biotechnology company. Dr. Aspeslet has over 20 years of progressive management and leadership experience in the pharmaceutical industry overseeing large operating budgets and dozens of multiple-phase clinical trials.
Mauro Chies
AHS Representative
Mauro is the Vice President of Cancer Control Alberta & Clinical Support Services, and member of the AHS Executive Leadership Team. Mauro has previously held the positions of Vice President (Acting), Clinical Support Services and Province-wide Services, as well as Senior Operating Officer, Diagnostic Imaging Services. He started his career with the former Capital Health region in 1988 as a medical laboratory technologist.
Advisory Committee
Our advisory committee’s high level skills and expertise in the industry help guide the processes and success of API’s partners and projects.
Launa Aspeslet
CEO, TRIO
Sailaja Bhaskar
Executive Director, R&D, Purdue Pharma
Brian Corrigan
Global Head, Clinical Pharmacology, Pfizer
Robert Foster
CEO, ContraVir
Matt Coffey
CEO, Oncolytics
Jamie Lucien
Biotech Patent Lawyer
Salma Jutt
VP US & Global Marketing, Abbott
Majid Vakilynejad
Senior Director, Takeda
Michael Houghton
Nobel Laureate and Director, Li Ka Shing Applied Virology Institute